Glucagon-Like Peptide-1 Receptor Agonists Beneficial As Add-On

Share this content:
Glucagon-Like Peptide-1 Receptor Agonists Beneficial As Add-On
Glucagon-Like Peptide-1 Receptor Agonists Beneficial As Add-On

FRIDAY, July 1, 2016 (HealthDay News) -- Lixisenatide and glulisine as add-on to basal insulin result in a reduction in glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, according to a study published online June 22 in Diabetes Care.

Julio Rosenstock, M.D., from the Dallas Diabetes and Endocrine Center at Medical City, and colleagues randomized overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without one to three oral antidiabetic agents. If HbA1c levels remained ≥7 to ≤9 percent after 12 weeks of glargine optimization, participants were randomized to lixisenatide once daily or insulin glulisine given once or three times daily.

The researchers found that the baseline characteristics were similar between the groups (298 patients). There was improvement in HbA1c seen with glargine optimization (from 8.5 to 7.9 percent), which further improved to 7.2, 7.2, and 7.0 percent, respectively, with lixisenatide and glulisine once daily and three times daily. All study coprimary end points were met. Lixisenatide versus glulisine patients had less symptomatic hypoglycemia and lower body weight. There were more gastrointestinal events with lixisenatide.

"Short-acting glucagon-like peptide-1 receptor agonists as add-on to basal insulin may become a preferred treatment intensification option, attaining meaningful glycemic targets with fewer hypoglycemic events without weight gain versus basal-plus or basal-bolus in uncontrolled basal insulin-treated type 2 diabetes," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which manufactures lixisenatide and sponsored the GetGoal Duo-2 trial.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »